Go Pro
→ On October 7th, your “safest” assets are at risk (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.38
+40.7%		$0.25
$0.12
▼
$3.00
N/AN/A4,472 shs1,806 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.01
$0.02
$0.01
▼
$0.23
N/AN/A55,136 shs2,563 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
$0.00
-7.6%		$0.01
$0.00
▼
$0.15
N/AN/A26,587 shs68,485 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%-12.90%-9.70%+58.45%-81.88%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%0.00%-4.13%-20.00%-39.27%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
-61.76%-73.47%-88.07%-88.60%-98.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.38
+40.7%		$0.25
$0.12
▼
$3.00
N/AN/A4,472 shs1,806 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.01
$0.02
$0.01
▼
$0.23
N/AN/A55,136 shs2,563 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
$0.00
-7.6%		$0.01
$0.00
▼
$0.15
N/AN/A26,587 shs68,485 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%-12.90%-9.70%+58.45%-81.88%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%0.00%-4.13%-20.00%-39.27%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
-61.76%-73.47%-88.07%-88.60%-98.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$491.95MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$8.50MN/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/A11/11/2026 (Estimated)
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)
Aravive, Inc stock logo
ARAV
Aravive
N/A-$0.90N/AN/AN/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A11/5/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
35.80%
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
60.40%
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
4N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
59N/AN/ANot Optionable
Aravive, Inc stock logo
ARAV
Aravive
20N/AN/ANo Data
Jasper Therapeutics, Inc. stock logo
JSPRW
Jasper Therapeutics
20N/AN/ANot Optionable

Recent News About These Companies

Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to NASDAQ Composite Index
September 19, 2026  |  marketscreener.comM
Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
September 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69591840-jasper-therapeutics-inc-jasper-therapeutics-announces-key-regulatory-and-clinical-appointments-399.htm
Jasper Therapeutics Appoints Regulatory, Clinical Executives For Pipeline Development; Stock Up
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691403/jasper-therapeutics-appoints-regulatory-clinical-executives-for-pipeline-development-stock-up.aspx
JSPRW - Jasper Therapeutics, Inc. WT EXP 092426
August 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/JSPRW
Analysts Offer Insights on Healthcare Companies: Aptevo Therapeutics (APVO) and Jasper Therapeutics (JSPR)
August 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/JSPR/pressreleases/3922916/analysts-offer-insights-on-healthcare-companies-aptevo-therapeutics-apvo-and-jasper-therapeutics-jspr/
Jasper Therapeutics beats Q2 expectations but shares fall after results
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/jasper-therapeutics-beats-q2-expectations-123026893.html
Jasper Therapeutics Inc. Wt
August 13, 2026  |  wsj.comhttps://www.wsj.com/market-data/quotes/JSPRW/research-ratings
JSPR Share News Today
July 16, 2026  |  uk.investing.comhttps://uk.investing.com/equities/amplitude-healthcare-acquisition-news/17
Analysts Have Conflicting Sentiments on These Healthcare Companies: Keros Therapeutics (KROS), Jasper Therapeutics (JSPR) and Corvus Pharmaceuticals (CRVS)
May 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/JSPR/pressreleases/1974311/analysts-have-conflicting-sentiments-on-these-healthcare-companies-keros-therapeutics-kros-jasper-therapeutics-jspr-and-corvus-pharmaceuticals-crvs/
TD Cowen downgrades Jasper Therapeutics (JSPR)
May 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/td-cowen-downgrades-jasper-therapeutics-jspr/ar-AA23k402
Jasper Therapeutics Inc : JSPRW
May 15, 2026  |  247wallst.comhttps://247wallst.com/companies/jsprw/
Jasper Therapeutics (JSPR) price target decreased by 13.33% to 7.73
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/jasper-therapeutics-jspr-price-target-decreased-by-1333-to-773/ar-AA23bPWd
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7
April 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/evercore-isi-lowers-price-target-142932139.html
Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss
March 31, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/jasper-therapeutics-shares-rise-5-on-clinical-updates-despite-q4-loss/ar-AA1ZPPpz
Jasper Therapeutics (JSPR) price target decreased by 30.92% to 8.92
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/jasper-therapeutics-jspr-price-target-decreased-by-3092-to-892/ar-AA1Zxfdl
JSPRW Jasper Therapeutics, Inc. WT EXP 092426
February 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/JSPRW/sec-filings
Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 14.63%
January 9, 2026  |  aaii.comA
Jasper Therapeutics reports updated data from briquilimab studies
January 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/jasper-therapeutics-reports-updated-data-121517783.html
RBC Capital Sticks to Its Hold Rating for Jasper Therapeutics (JSPR)
December 6, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/JSPR/pressreleases/36451801/rbc-capital-sticks-to-its-hold-rating-for-jasper-therapeutics-jspr/
Jasper Shares Surge Following Encouraging Early Asthma Trial Data
December 2, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/jasper-shares-surge-following-encouraging-early-asthma-trial-data/ar-AA1Rz7Hy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.38 +0.11 (+40.70%)
As of 10:05 AM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.01 0.00 (0.00%)
As of 09/23/2026 11:16 AM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 09/23/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Jasper Therapeutics stock logo

Jasper Therapeutics NASDAQ:JSPRW

$0.0012 0.00 (-7.58%)
As of 11:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas